Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: A prospective analysis

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Boyle, Andrew J ^a,b   Di Gangi, Stefania ^c   Hamid, Umar I ^a   Mottram, Linda Jayne ^b   McNamee, Lia ^b   White, Griania ^b   Cross, Mark ^a,b   McNamee, James J ^b   O'Kane, Cecilia M ^a   McAuley, Daniel F ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c ASL TO3   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYPERTENSIVE FACTOR; ANTITHROMBOCYTIC AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTICOAGULANT THERAPY; APACHE; ARTICLE; DEMOGRAPHY; DRUG USE; EMERGENCY CARE; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK REDUCTION; HOSPITAL MORTALITY; ODDS RATIO; REGRESSION ANALYSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK;

ASPIRIN; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK;

EID: 84925342971     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0846-4     Document Type: Article

References (42)

1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685-93.
2. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683-93.
3. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293-304.
4. Perkins GD, Nathani N, McAuley DF, Gao F, Thickett DR. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax. 2007;62:36-42.
5. Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195-9.
6. Frank JA, Wray CM, McAuley DF, Schwendener R, Matthay MA. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Am J Physiol - Lung Cell Mol Physiol. 2006;291:L1191-8.
7. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-49.
8. Boyle AJ, Sweeney RM, McAuley DF. Pharmacological treatments in ARDS; a state-of-the-art update. BMC Med. 2013;11:166.
9. Boyle AJ, McNamee JJ, McAuley DF. Biological therapies in the acute respiratory distress syndrome. Expert Opin Biol Ther. 2014;14:969-81.
10. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-8.
11. Guérin C, Reignier J, Richard J-C, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159-68.
12. Papazian L, Forel J-M, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107-16.
13. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. The Lancet. 2009;374:1351-63.
14. Fitzgerald M, Millar J, Blackwood B, Davies A, Brett SJ, McAuley DF, et al. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care. 2014;18:222.
15. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116:3211-9.
16. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119:3450-61.
17. Bates JJ, Watson RWG, Glynn CM, O'Neill AJ, Fitzpatrick JM, Buggy DJ. Aspirin preserves neutrophil apoptosis after cardiopulmonary bypass. Shock Augusta Ga. 2004;21:495-9.
18. Kor DJ, Erlich J, Gong MN, Malinchoc M, Carter RE, Gajic O, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med. 2011;39:2393-400.
19. O'Neal HR, Koyama T, Koehler EAS, Siew E, Curtis BR, Fremont RD, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and ALI/ARDS. Crit Care Med. 2011;39:1343-50.
20. Harr JN, Moore EE, Johnson J, Chin TL, Wohlauer MV, Maier R, et al. Antiplatelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients. Crit Care Med. 2013;41:399-404.
21. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest. 2011;139:289-95.
22. Ahmed AHM, Litell JMD, Malinchoc MM, Kashyap RM, Schiller HJ, Pannu SRM, et al. The role of potentially preventable sospital exposures in the development of acute respiratory distress syndrome: A population-based study. Crit Care Med. 2014;42:31-9.
23. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, et al. Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms. Platelets. 2009;20:50-7.
24. Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med. 2012;40:1761-7.
25. Sossdorf M, Otto GP, Boettel J, Winning J, Lösche W. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care. 2013;17:402.
26. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-24.
27. The ARDS Definition Task Force. Acute respiratory distress syndrome: The Berlin definition. JAMA. 2012;307:2526-33.
28. Wood AJJ, Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-94.
29. Tuinman PR, Müller MC, Jongsma G, Hegeman MA, Juffermans NP. High-dose acetylsalicylic acid is superior to low-dose as well as to clopidogrel in preventing lipopolysaccharide-induced lung injury in mice. Shock Augusta Ga. 2013;40:334-8.
30. Sun Y-P, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, et al. Resolvin D1 and its aspirin-triggered 17R epimer stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323-34.
31. Eickmeier O, Seki H, Haworth O, Hilberath J, Gao F, Uddin M, et al. Aspirin-Triggered-Resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol. 2013;6:256-66.
32. Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Jonas M, et al. Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;156:1969-77.
33. El Kebir D, József L, Pan W, Wang L, Petasis NA, Serhan CN, et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med. 2009;180:311-9.
34. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 2009;183:2089-96.
35. Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2010;38:32-7.
36. Mahajan R, Heptinstall S. Should critical care patients receive or remain on treatment with antiplatelet drugs? Crit Care Med. 2010;38:298-300.
37. McAuley DF, Laffey JG, O'Kane CM, Perkins GD, Mullan B, Trinder TJ, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695-703.
38. The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370:2191-200.
39. Rocker G, Cook D, Sjokvist P, Weaver B, Finfer S, McDonald E, et al. Clinician predictions of intensive care unit mortality. Crit Care Med. 2004;32:1149-54.
40. The Irish Critical Care Trials Group. Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care. 2008;12:R30.
41. Hsieh SJ, Zhuo H, Benowitz NL, Thompson BT, Liu KD, Matthay MA, et al. Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome. Crit Care Med. 2014;42:2058-68.
42. Kor DJ, Talmor DS, Banner-Goodspeed VM, Carter RE, Hinds R, Park PK, et al. Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open. 2012;2.